Efficacy of first-line treatments for patients (pts) with advanced EGFR mutated NSCLC: Network meta-analysis of TKI monotherapy and combinations trials.

作者
Alexey A. Bogdanov,Fedor Vladimirovich Moiseenko,Альбина Сергеевна Жабина,Никита Михайлович Волков,Elizaveta Artemeva,Mikhail Yu. Fedyanin
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): e21120-e21120 被引量:1
标识
DOI:10.1200/jco.2021.39.15_suppl.e21120
摘要

e21120 Background: Various EGFR TKIs and several combinations are the standard of initial treatment for NSCLC with EGFR mutations. For this moment one size fits all approach is used. Due to the limited nature of this subgroup direct prospective survival comparison of various options is time and resource consuming. The main objective of this study was to compare available prospective trials in a network meta-analysis in order to determine the overall survival (OS) advantage. Methods: Using frequentist approach (netmeta R package) we performed a network meta-analysis of prospective randomized trials comparing having platinum doublet or 1G TKI as a control arm and 1G TKI, 2G TKI, 3G TKI, combination of chemotherapy (CT)+1G TKI, combination anti-VEGF/R+1G TKI as investigation arm in pts with EGFRmut NSCLC. Between trials we compared OS and progression free survival (PFS ) for overall population and subgroups by mutation, sex, age, smoking status. Results: 17 trials involved 4671 pts were considered eligible for meta-analysis. Trials investigated various combinations of TKIs in untreated EGFR mutated NSCLC: 8 had chemotherapy (CT) as control arm (ENSURE, EURTAC, IPASS, NEJ002, OPTIMAL CTONG-0802, WJTOG3405, LUX-Lung-3/6) and 9 with 1G TKIs as control arm (JO25567, NEJ026, 14034 H3E-CR-JIMIT, NEJ009, Noronha et. al, LUX-LUNG7, ARCHER1050, SWOGS1403, FLAURA). Compared to 1G TKIs improved OS was observed for combination of 1G TKI and CT (HR 0.64 (0.53– 0.78)), 3G TKIs (HR 0.80 (0.64-1.00)), 2G TKIs (HR 0.83 (0.72-0.96)) (The OS benefit was ranked No.1 for TKI+chemo (P-score – 0.96), No.2 – 3G TKI (P-score – 0.68), No.3 – 2G TKI (P-score – 0.64)) Addition of anti-VEGF/R therapy did not improve OS (HR 0.91 (0.68-1.21) over 1G TKIs alone. Importantly OS advantage remained significant in a subgroup of ex19del only for 2G TKIs (HR 0.71 (0.53-0.96)). No advantage for particular regimen was seen for L858R subgroup. 3G TKIs (HR 0.46 (0.27-0.78)), combinations with CT (HR 0.55 (0.40-0.75)) and anti-angiogenic agents (HR 0.57 (0.37-0.89), improved PFS over 1GTKIs, while 2G TKIs had a tendency for improving (HR 0.78 (0.58-1.06)). Conclusions: Our network meta-analysis showed that compared to initial treatment with 1G TKI monotherapy - 1G combination with CT, monotherapy with 3G and 2G may provide OS advantage. Still for ex19del subgroup OS benefit was significant only for 2G TKI. The availability of multiple first line options force the importance of stratification of patients for particular treatment type.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhangyupei发布了新的文献求助30
刚刚
热心市民小红花完成签到,获得积分0
刚刚
长言完成签到 ,获得积分10
刚刚
sljzhangbiao11完成签到,获得积分10
刚刚
疯狂加载ing的应助被时平谊采纳,获得10
1秒前
Hello的应助被ykyin采纳,获得10
1秒前
1秒前
2秒前
AK完成签到,获得积分20
2秒前
2秒前
BUILUE关注了科研通微信公众号
2秒前
yjh完成签到,获得积分10
3秒前
yme7o完成签到,获得积分10
3秒前
黎秣完成签到,获得积分10
3秒前
小宇神男人完成签到,获得积分20
3秒前
lnvvl完成签到 ,获得积分10
3秒前
张米完成签到,获得积分10
3秒前
熏风完成签到,获得积分10
3秒前
实验室发布了新的文献求助10
3秒前
江波完成签到,获得积分10
3秒前
哎哟喂完成签到,获得积分10
3秒前
爆米花的应助被111采纳,获得10
4秒前
迪迪张发布了新的文献求助10
4秒前
SciGPT的应助被潆星采纳,获得10
4秒前
www完成签到 ,获得积分10
4秒前
Akim的应助被LEETHEO采纳,获得10
5秒前
5秒前
5秒前
5秒前
zy完成签到 ,获得积分10
5秒前
orixero的应助被焦糖布丁采纳,获得10
6秒前
zyy发布了新的文献求助10
6秒前
Orange的应助被闪闪晓绿采纳,获得10
6秒前
6秒前
野性的飞机完成签到 ,获得积分10
6秒前
SYY完成签到,获得积分10
6秒前
华赛发布了新的文献求助10
6秒前
Chambray发布了新的文献求助50
6秒前
6秒前
傻傻的灵寒完成签到 ,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253